Preparation of [76Br]FLB 457 and [76Br]FLB 463 for examination of striatal and extrastriatal dopamine D-2 receptors with PET

Nuclear Medicine and Biology

Volumn 23, Issue 6, 1996, Pages 813-819

  Loc'h, Christian ^a,c   Halldin, Christer ^b   Bottlaender, Michel ^a   Swahn, Carl Gunnar ^b   Moresco, Rosa Maria ^a   Mazière, Mariannick ^a   Farde, Lars ^b   Mazière, Bernard ^a  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c DIF   (France)

Author keywords

bromine 76; dopamine D 2 receptor antagonist; extrastriatal binding; positron emission tomography; substituted benzamide

Indexed keywords

3 BROMO N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 5,6 DIMETHOXYBENZAMIDE; BENZAMIDE DERIVATIVE; BROMINE 76; DOPAMINE 2 RECEPTOR; FLB 465; ISOREMOXIPRIDE; UNCLASSIFIED DRUG; BROMINE; DIAGNOSTIC AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; PYRROLIDINE DERIVATIVE; SALICYLAMIDE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BABOON; CONTROLLED STUDY; CORPUS STRIATUM; DRUG SYNTHESIS; ISOTOPE LABELING; POSITRON EMISSION TOMOGRAPHY; ANIMAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; MALE; METABOLISM; PAPIO; SCINTISCANNING; SYNTHESIS; THIN LAYER CHROMATOGRAPHY; ULTRASTRUCTURE;

ANIMALS; BROMINE RADIOISOTOPES; CHROMATOGRAPHY, THIN LAYER; CORPUS STRIATUM; DOPAMINE ANTAGONISTS; MALE; PAPIO; PYRROLIDINES; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030203687     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/0969-8051(96)00078-9     Document Type: Article

References (33)

1. 123I]2′-ISP in nonhuman primates. Nucl. Med. Biol. 21, 969-976.
2. 2. Bendriem B., Trebossen R., Frouin V., Lamer O., Brulon V. and Syrota A. (1992) Evaluation of a PET scanner in 2D and 3D acquisition mode. In: Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society (Edited by Moussy J-P., Plonsey R-, Coatrieux J-L. and Laxminarayan S.), Vol. 14, pp. 1837-1840.
3. 3. Blanchard J. (1981) Evaluation of the relative efficacy of various techniques of deproteinizing plasma samples prior to high-performance liquid chromatography analysis. J. Chromatogr. 226, 455-460.
4. 125I]epidepride: A dopamine D2 receptor antagonist radioligand. J. Label. Compd. Radiopharm. 29, 745-751.
5. 5. Coenen H. H., Moerlein S. M. and Stöcklin G. (1983) No-carrier added radiohalogenation methods with heavy halogens. Radiochim. Acta 34, 47-68.
6. 76Br]bromolisuride binding to dopamine D2 receptors studied by PET. J. Cereb. Blood Flow Metab. 11, 914-925.
7. 11C-raclopride in the living human brain - A search for extrastriatal central D-2 dopamine receptors by PET. Psychopharmacology 94, 471-478.
8. 8. Farde L., Hall H., Ehrin E. and Sedvall G. (1986) Quantitative analysis of dopamine D-2 receptor binding in the living human brain by positron emission tomography. Science 231, 258-261.
9. 9. Hall H., Halldin C., Loc'h C., Bourguignon M., Syrota A., Mazière M., Sedvall G., Salomonsson M., Mazière B. and Farde L. (1995) Differences in SPECT visualization of extra-striatal D2 dopamine receptors with epidepride and NCQ 298 are not verified in in vitro human whole hemisphere autoradiography. Eur. J. Nucl. Med. 8, 824 (Abstract).
10. 10. Hall H., Högberg T., Halldin C., Köhler C., Ström P., Ross S. B., Larsson S. A. and Farde L. (1991) NCQ 298, a new selective iodinated salicylamide ligand for the labelling of dopamine D-2 receptors. Psychopharmacology 103, 6-18.
11. 11. Halldin C., Farde L., Högberg T., Mohell N., Hall H., Suhara T., Karlsson P., Nakashima Y. and Swahn C-G. (1995) [C-11]FLB 457: A radioligand for extrastriatal dopamine D-2 receptors. J. Nucl. Med. 36, 1275-1281.
12. 12. Halldin C., Högberg T. and Farde L. (1994) Fluorine-18-labelled NCQ 115, a selective dopamine D-2 receptor ligand: Preparation and positron emission tomography. Nucl. Med. Biol 21, 627-631.
13. 13. Halldin C., Farde L., Högberg T., Hall H., Ström P., Ohlberger A. and Solin O. (1991) A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides: Preparation and in vitro dopamine D-2 receptor binding. Nucl. Med. Biol. 18, 871-881.
14. 14. Högberg T., Ström P., de Paulis T., Stensland B., Csöregh I., Lundin K., Hall H. and Ögren S. O. (1991) Potential antipsychotic agents: 9. Synthesis and Stereoselective D-2 receptor blockade of a potent class of substituted (R)-N-[(1-benzyl-2-pyrrolidnyl)merhyl]benzamides: Relations to other side chain congeners. J. Med. Chem. 34, 948-955.
15. 125I]-and unlabelled (S)-iodo-5,6-dimethoxy-N-[(1-erhyl-2-pyrrolidinyl)-methyl]salicylamide (NCQ 298), selective ligands for the study of dopamine D-2 receptors. Acta Pharm. Nord. 1, 53-60.
16. 16. Högberg T., de Paulis T., Johansson L., Kumar, Y., Hall H. and Ögren S. O. (1990) Potential antipsychotic agents:7. Synthesis and antidopaminergic properties of the atypical highly potent (S)-5-bromo-2,3-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)-methyl]benzamide and related compounds: A comparative study. J. Med. Chem. 33, 2305-2309.
17. 17. Högberg T., Bengtsson S., de Paulis T., Johansson L., Ström P., Hall H. and Ögren S. O. (1990) Potential antipsychotic agents: 5. Synthesis and antidopaminergic properties of substituted 5,6-dimethoxysalicylamides and related compounds. J. Med. Chem. 33, 1155-1163.
18. 125I]epidepride. Brain Res. 609, 237-243.
19. 125I]epidepride: In vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. Life Sci. 53, 241-250.
20. 20. Kessler R. M., Mason N. S., Votaw J. R., de Paulis T., Clanton J. A., Ansari S. M., Schmidt D. E., Manning R. G. and Bell R. L. (1992) Visualization of extrastriatal dopamine D-2 receptors in the human brain. Eur. J. Pharmacol. 223, 105-107.
21. 125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors. Life Sci. 49, 617-628.
22. 22. Lassen N. A. (1996) A reappraisal of the relative merits of SPET and PET in the quantitation of neuroreceptors: The advantage of a longer half-life! Eur. J. Nucl. Med. 23, 1-4.
23. 23. Lassen N. A. (1992) Neuroreceptor quantitation in vivo by the steady-state principle using constant infusion or bolus injection of radioactive tracers. J. Cereb. Blood Flow Metab. 12, 709-716.
24. 24. Loc'h C., Halldin C., Bourguignon M., Syrota A., Mazière M., Farde L. and Mazière B. (1995) In vivo extrastriatal binding on dopamine D-2 receptors of radiolabelled benzamides and salicylamides. J. Nucl. Med. 36, 256P (Abstract).
25. 76Br]NCQ 115, three selective benzamides for mapping dopamine D-2 receptors with PET. J. Label. Compd. Radiopharm. 35, 437-438.
26. 26. Maziere B., Cantineau R., Coenen H. H., Guillaume M., Halldin C., Luxen A., Loc'h C. and Luthra S. K. (1993) PET Radiopharmaceutical metabolism: Plasma metabolite analysis. In: Radiopharmaceutical for Positron Emission Tomography (Edited by Stöcklin G. and Pike V. W.), pp. 151-178. Klüwer, Dordrecht, The Netherlands.
27. 27. Maziere B. and Loc'h C. (1986) Bromine radiopharmaceuticals:Radiopharmaceuticals labelled with bromine isotopes. Appl. Radiat. Isot. 37, 703-713.
28. 76Br]bromolisuride: A new tool for quantitative in vivo imaging of D-2 dopamine receptors. Eur. J. Pharmacol. 127, 239-247.
29. 29. Mohell N., Sallemark M., Rosqvist S., Malmerg A., Högberg T. and Jackson D.M. (1993) Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors. Eur. J. Pharmacol. 238, 121-125.
30. 30. Riche D., Hantraye P., Guibert B., Naquet R., Loc'h C., Mazière B. and Mazière M. (1988) Anatomical atlas of baboon's brain in the orbitomeatal plane used in positron emission tomography. Brain Res. Bull. 20, 283-301.
31. 31. Schmidt D. E., Votaw J. R., Kessler R. M. and de Paulis T. (1994) Aromatic and amine substituent effects on the apparent lipophilicities of N-[(2-pyrrolidinyl)methyl]-substituted benzamides. J. Pharm. Sci. 83, 305-315.
32. 11C]SCH 23390: Identification of two metabolites with HPLC. Hum. Psychopharmacol. 9, 25-31.
33. 33. Wang G-J., Volkow N. D., Fowler N. S., Wolf A. P., Mac Gregor R. R., Shea C. E., Schlyer D. J. and Hitzemann R. J. (1993) Comparison of two PET radioligands for imaging extrastriatal dopamine receptors in the human brain. Synapse 15, 246-249.